<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00554255</url>
  </required_header>
  <id_info>
    <org_study_id>108543</org_study_id>
    <nct_id>NCT00554255</nct_id>
  </id_info>
  <brief_title>A Study of SB751689 in Japanese Postmenopausal Women</brief_title>
  <official_title>Phase I Study of SB751689 - Single and Multiple Oral Dose Study in Japanese Postmenopausal Women -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day
      multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, change in clinical laboratory tests, vital signs, 12lead ECG</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and Pharmacodynamics of SB751689</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB751689</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is considered as healthy by the investigator at screening.

          -  Healthy subjects are defined as individuals who are free from clinically significant
             illness or disease as determined by their medical history, physical examination,
             laboratory studies, and other tests

          -  Japanese healthy postmenopausal woman as defined as being amenorrheic for at least 1
             year at screening with &lt;157.79mIU/mL of FSH levels.

          -  Body weight &gt;= 45 kg and BMI within the range 18.5 -25.0 kg/m2.

          -  The subject is within the following criteria as screening;Liver function tests (ALT,
             AST, GGT, alkaline phosphatase, total bilirubin), CPK, serum parathyroid hormone
             (iPTH) test, vitamin D (1,25(OH2 D3)) levels, Serum calcium

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Non-smokers (at least 6 months)

          -  The subject is able to attend all visits and complete the study.

        Exclusion Criteria:

          -  The subject has any clinically relevant abnormality on medical examination, vital
             sign, clinical laboratory test or medical history at screening in the medical opinion
             of the investigator or the subject has a medical history that is not considered as
             eligible for inclusion in this study by the investigator.

          -  History of sensitivity to any of the study medications or components thereof (except
             pollenosis without any signs or symptoms).

          -  Participation in a clinical study or post-marketing study with an investigational or a
             non-investigational product or device within 4 months of preceding the first dose of
             study medication.

          -  Participation in another clinical study or post-marketing study in which the subject
             is or will be exposed to an investigational or a non-investigational product or
             device.

          -  Positive for syphilis, HIV antibody, hepatitis B antigen or hepatitis C antibody,
             HTLV-1 antibody at screening.

          -  Positive urine drug screen at screening.

          -  Donation of blood in excess of 400 mL within the previous 4 months or 200mL within the
             previous 1 month of screening.

          -  Use of prescription or non-prescription drugs, herbal and dietary supplements, within
             14 days prior to the first dose of study medication.

          -  History of drug abuse or current conditions of drug abuse or alcoholism.

          -  History of regular alcohol consumption exceeding 7 units/week (&gt;350mL of beer/unit)
             within 6 months of screening.

          -  Subjects with a history of renal, hepatic, or biliary disease.

          -  History of clinically significant cardiovascular disease.

          -  History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones.

          -  Subjects who have had history of significant gastrointestinal disease (e.g.,
             gastrointestinal malabsorptive disease, colostomy, chronic gastroesophageal reflux
             disease, Crohn's disease, ulcerative colitis, gastric or duodenal ulcer,
             gastrointestinal tract bleeding, short bowel syndrome, sprue, lactose intolerance,
             irritable bowel syndrome).

          -  Subjects with any history of a gastrointestinal surgical procedure that might affect
             the absorption of SB-751689 (e.g. cholecystectomy, gastrointestinal bypass surgery,
             partial or total gastrectomy, small bowel resection).

          -  Medical conditions which might alter bone metabolism, including hyperparathyroidism,
             hypoparathyroidism, hyperthyroidism, hypothyroidism, Paget's disease, malabsorption,
             or Cushing's syndrome, and hypogonadism, hypocalcemia, hypercalcemia,
             hypophosphatemia, hypomagnesemia, hypermagnesemia, osteopetrosis, osteomalacia, and
             recent (within one year) history of fracture or prolonged bedrest.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2007</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Japanese</keyword>
  <keyword>safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

